ArticleTargeted oncology2021

Prognostic Impact of Early Treatment Interruption of Nivolumab Plus Ipilimumab Due to Immune-Related Adverse Events as First-Line Therapy for Metastatic Renal Cell Carcinoma: A Multi-Institution Retrospective Study.

Hiroki Ishihara et al.PubMed ↗Publisher ↗

No numbers read from the abstract.